| Ticker: CHRX | 33 Locke Drive | |
| Exchange: NASDAQ-National Market | Marlborough, Massachusetts 01752 | |
| Industry: Manufacturing | (508) 460-1212 |
| Type of Shares: | Common Shares | Filing Date: | 12/26/95 | |
| U.S. Shares: | 5,340,000 | Offer Date: | 3/5/96 | |
| Non-U.S. Shares: | 1,335,000 | Filing Range: | $12.00 - $14.00 | |
| Primary Shares: | 6,675,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.91 | |
| Offering Amount: | $86,775,000 | Selling: | $0.54 | |
| Expenses: | $1,600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 10,843,389 |
| Manager | Tier | Phone |
| CS First Boston | Lead Manager | (212) 909-3312 |
| Lehman Brothers Incorporated | Co-manager | (212) 640-6129 |
| Smith Barney Inc. | Co-manager | (718) 921-8473 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 12/31/95 | ||||
| Revenue: | $90.43 | Assets: | $128.68 | ||
| Net Income: | -$3.02 | Liabilities: | $82.70 | ||
| EPS: | -$0.10 | Equity: | $45.98 | ||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company markets chemicals, including pharmaceutical intermediates and active ingredients. The company is a unique combination of (i) a chiral chemistry business with patented and proprietary technologies, (ii) a well-established pharmaceutical fine chemical business with significant operating leverage and (iii) a vertically integrated generic drug joint venture. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used to finance combinations and mergers, repay bank debt and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.